Concurrent radiochemotherapy in advanced hypopharyngeal cancer

被引:12
|
作者
Krstevska, Valentina [1 ]
Stojkovski, Igor [1 ]
Lukarski, Dusko [2 ]
机构
[1] Univ Clin Radiotherapy & Oncol, Dept Head & Neck Canc, Skopje, North Macedonia
[2] Univ Clin Radiotherapy & Oncol, Dept Radiat Phys, Skopje, North Macedonia
关键词
SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; ONCOLOGY GROUP RTOG; RADIATION-THERAPY; NECK-CANCER; ADVANCED LARYNGEAL; RANDOMIZED-TRIAL; ACCELERATED RADIOTHERAPY; EUROPEAN-ORGANIZATION; ORGAN PRESERVATION;
D O I
10.1186/1748-717X-5-39
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Concurrent platinum-based radiochemotherapy has been recommended as a standard of care in patients with locally advanced squamous cell head and neck carcinomas. Unfortunately, there is a lack of level one evidence on best treatment approach for advanced hypopharyngeal cancer. This report aims to summarize the results of our study on concurrent radiochemotherapy in patients with advanced hypopharyngeal cancer. Methods: A retrospective analysis of 41 patients with stage III-IV hypopharyngeal cancer was performed. All patients were treated with three dimensional conformal radiotherapy and received 70 Gy in 35 fractions (2 Gy per fraction, 5 fractions per week). In dependence of the period when radiotherapy was realized, two different treatment techniques were used. Concurrent chemotherapy consisted of cisplatin 30 mg/m(2) given on a weekly basis. Results: The median age was 52 years (range 29-70). Stage IV disease was recognized in 73.2% of the patients. Complete response rates at the primary site and at the metastatic neck lymph nodes were 68.3% and 36.6%, respectively. A complete composite response was present in 27 patients (65.9%). Median follow-up was 13 months (range 7-36). Distant metastases as initial failure occurred in 7 patients (46.7%). The 2-year local relapse-free survival and regional relapse-free survival rates were 55.2% and 75.8%, respectively. The 2-year locoregional relapse-free survival rate was 51.3%. The 2-year disease-free survival and overall survival rates were 29.3% and 32.8%, respectively. Confluent mucositis was developed in 46.3% of patients. Leucopenia grade 1 was the most frequent hematological toxicity. The median weight loss at the end of treatment was 12% (range 5-21). The worst grade of late toxicity was most commonly pronounced in the skin and in the subcutaneous tissue. Conclusions: Based on unsatisfactory results in our study we suggest that the use of sequential radiochemotherapy or chemotherapy given concomitantly with altered fractionation radiotherapy with the implementation of intensity-modulated radiotherapy as radiotherapy technique could represent treatment approaches able to improve outcome in patients with advanced hypopharyngeal cancer.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Concurrent radiochemotherapy in advanced hypopharyngeal cancer
    Valentina Krstevska
    Igor Stojkovski
    Dusko Lukarski
    Radiation Oncology, 5
  • [2] CONCURRENT RADIOCHEMOTHERAPY IN ADVANCED BREAST-CANCER
    MEEK, AG
    ORDER, SE
    ABELOFF, MD
    ETTINGER, D
    BAKER, RR
    BARAL, E
    CANCER, 1983, 51 (06) : 1001 - 1006
  • [3] The efficacy of concurrent radiochemotherapy in women with advanced cervical cancer
    Roszak, A.
    Cikowska-Wozniak, E.
    Wlodarczyk, H.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S304 - S304
  • [4] Concurrent radiochemotherapy with Gemcitabine for locally advanced bladder cancer
    Cringeanu, A.
    Stanculeanu, D.
    Savu, M.
    Minea, L. N.
    Mitulescu, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 251 - 252
  • [5] Concurrent chemoradiotherapy for advanced hypopharyngeal or cervical esophageal cancer
    Endo, S
    Kida, A
    Hamada, N
    Watanabe, Y
    Nakazato, H
    Shigihara, S
    Watanabe, K
    Ootsuka, K
    Suzuki, S
    Kobayashi, D
    BRONCHOLOGY AND BRONCHOESOPHAGOLOGY: STATE OF THE ART, 2001, 1217 : 491 - 493
  • [6] Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer
    Kogashiwa, Yasunao
    Yamauchi, Kohichi
    Nagafuji, Hiroshi
    Matsuda, Takehiro
    Tsubosaka, Toshihito
    Tsutsumi, Tomoko
    Karaho, Takehiro
    Kohno, Naoyuki
    ONCOLOGY REPORTS, 2009, 22 (05) : 1163 - 1167
  • [7] Radiotherapy and concurrent radiochemotherapy for rectal cancer
    Rödel, C
    Sauer, R
    SURGICAL ONCOLOGY-OXFORD, 2004, 13 (2-3): : 93 - 101
  • [8] Induction chemotherapy (IC) followed by radiochemotherapy (RCT) versus radiochemotherapy alone as treatment in advanced laryngeal (LC)/hypopharyngeal cancer (HC): Phase IIb
    Knecht, Rainald
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer
    Wen-Yen Huang
    Yee-Min Jen
    Chang-Ming Chen
    Yu-Fu Su
    Chun-Shu Lin
    Yaoh-Shiang Lin
    Ying-Nan Chang
    Hsing-Lung Chao
    Kuen-Tze Lin
    Li-Ping Chang
    Radiation Oncology, 5
  • [10] Functional outcome after concurrent chemoradiation in patients with locally advanced laryngeal or hypopharyngeal cancer
    Madoka, Furukawa K.
    Kubota, A.
    Yagi, H.
    Masaki, Furukawa
    17TH WORLD CONGRESS FOR BRONCHOLOGY AND INTERVENTIONAL PULMONOLOGY / 17TH WORLD CONGRESS FOR BRONCHOESOPHAGOLOGY, 2013, : 7 - 9